Two signaling targets along the MAPK pathway in treating melanoma are mutated serine/threonine-protein kinase B-Raf (BRAF) [11,12] and mitogen-activated protein kinase kinase (MEK) [13]. Here, MAP2K7 is linked to melanoma.